IDYA IDEAYA Biosciences Inc.

9.7
-0.33  -3%
Previous Close 10.03
Open 9.9
Price To Book 1.79
Market Cap 197,211,622
Shares 20,331,095
Volume 35,667
Short Ratio
Av. Daily Volume 50,880
Stock charts supplied by TradingView

NewsSee all news

  1. IDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020

    SOUTH SAN FRANCISCO, Calif., Jan. 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  2. IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ

    SOUTH SAN FRANCISCO, Calif., Jan. 10, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics,

  3. IDEAYA Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020

    SOUTH SAN FRANCISCO, Calif., Jan. 6, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  4. IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  5. IDE196 Program Updates: Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020

    SOUTH SAN FRANCISCO, Calif., Dec. 9, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 interim data expected in 2Q/3Q 2020.
IDE196
Solid tumors
Phase 1 trial ongoing - one complete response confirmed October 31, 2019.
IDE196
Uveal Melanoma

Latest News

  1. IDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020

    SOUTH SAN FRANCISCO, Calif., Jan. 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  2. IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ

    SOUTH SAN FRANCISCO, Calif., Jan. 10, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics,

  3. IDEAYA Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020

    SOUTH SAN FRANCISCO, Calif., Jan. 6, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  4. IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  5. IDE196 Program Updates: Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020

    SOUTH SAN FRANCISCO, Calif., Dec. 9, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  6. Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress

    SOUTH SAN FRANCISCO, Calif., Nov. 20, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  7. Phase 1/2 Clinical Trial Progress for IDE196 to be Presented at Society for Melanoma Research Congress

    SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  8. IDEAYA Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for

  9. IDEAYA Biosciences Announces Leadership Updates in Research Organization

    SOUTH SAN FRANCISCO, Calif., Nov. 5, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to

  10. IDEAYA Biosciences Reports End‑of‑Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma

    SOUTH SAN FRANCISCO, Calif., Oct. 31, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for